GRI

GRI Bio Inc.

NASDAQ: GRI · HEALTHCARE · BIOTECHNOLOGY

$2.26

-6.10% today

Updated 2026-06-05

Market cap

$3.98M

P/E ratio

0.06

P/S ratio

—

EPS (TTM)

$38.89

Dividend yield

—

52W range

$2 – $80

Volume

0.1M

Market cap

$3.98M

P/E ratio

0.06

P/S ratio

—

EPS (TTM)

$38.89

Dividend yield

—

52W range

$2 – $80

Volume

0.1M

WallStSmart proprietary scores

out of 100

Grade: F

Strong Sell

Investment rating

4.3

Growth

6.5

Quality

3.0

Profitability

6.7

Valuation

2/9

Piotroski F-Score

Weak

-10.7

Altman Z-Score

Distress

—

Industry rank

—

View all highly rated stocks (75+) →202 stocks currently score above 75

Price targets

Analyst target

$21.00

+829.20%

12-Month target

—

Intrinsic (DCF)

—

Margin of safety

—

0 Strong Buy2 Buy0 Hold0 Sell0 Strong Sell

Price chart

Stock snapshot

Strengths

+ Debt/equity 0.01x — low leverage

Risks

- Piotroski 2/9 — weak financial health

- Altman Z -10.73 — distress zone

- Thin margins at 0.00%

- Negative free cash flow $-3.69M

Key financials

Revenue Net Income Free Cash Flow

Metric	2022	2023	2024	2025	TTM
Revenue	$0.00	$21.77M	$22.54M	$0.00	$0.00
Net income	$-3.22M	$-13.04M	$-8.21M	$-11.96M	$-2.00M
EPS	—	—	—	—	$38.89
Free cash flow	$-1.09M	$-9.00M	$-8.61M	$-10.19M	$-3.69M
Profit margin	—	-59.89%	-36.41%	—	—

Peer comparison

Company	Mkt Cap	Score	Growth	Profit	Value	Quality	MoS	Rating
GRI	$3.98M	26	4.3	3.0	6.7	6.5	—	Avoid
LLY	$948.95B	78	10.0	10.0	5.0	6.0	—	Strong Buy
JNJ	$536.54B	59	4.7	9.0	3.3	6.0	-71.41%	Buy
ABBV	$380.57B	63	4.0	8.0	4.0	5.0	-55.64%	Buy
UNH	$343.21B	54	5.3	5.5	4.7	5.5	-26.61%	Buy
MRK	$285.64B	50	3.3	8.0	2.7	5.0	-49.34%	Hold

Smart narrative

GRI Bio Inc. trades at $2.26. representing a P/E of 0.06x trailing earnings. Our Smart Value Score of 26/100 indicates the stock is weak. The company scores 2/9 on the Piotroski F-Score. With an Altman Z-Score of -10.73, it sits in the distress.

Frequently asked questions

What is GRI Bio Inc.'s stock price?

GRI Bio Inc. (GRI) trades at $2.26, on a P/E of 0.1x. Those multiples show what the market is paying for each dollar of earnings and sales, which is the real starting point for judging whether the price is reasonable.

Is GRI Bio Inc. overvalued?

GRI Bio Inc. carries a Smart Value Score of 26/100 (Grade F), which we rate Strong Sell. That score blends growth, quality, and valuation into one read.

What is the price target of GRI Bio Inc. (GRI)?

The 12-month analyst consensus target is $21.00, about 829.2% above the current $2.26. A consensus target is the average of Wall Street's 12-month forecasts, so it works as a sentiment gauge rather than a guarantee, and it resets with every earnings cycle.

Altman Z-Score?

GRI Bio Inc.'s Altman Z-Score is -10.73, which places it in the distress. The Altman Z-Score gauges bankruptcy risk from profitability, leverage, and asset efficiency, and a higher reading points to lower financial distress risk.

Company info

SectorHEALTHCARE

IndustryBIOTECHNOLOGY

CountryUSA

ExchangeNASDAQ

CurrencyUSD

www.gribio.com

Quick metrics

P/S ratio—

ROE-103.44%

Beta-0.77

50D MA$2.27

200D MA$21.43

Shares out0.00B

Float0.00B

Short ratio—

Avg volume0.1M

Performance

1 week—

1 month—

3 months—

YTD—

1 year—

3 years—

5 years—

Compare

GRI vs LLY →GRI vs JNJ →GRI vs ABBV →Stock screener →